SYN-Tech Chem & Pharm Co Ltd (1777) - Total Liabilities

Latest as of December 2025: NT$369.57 Million TWD ≈ $11.64 Million USD

Based on the latest financial reports, SYN-Tech Chem & Pharm Co Ltd (1777) has total liabilities worth NT$369.57 Million TWD (≈ $11.64 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SYN-Tech Chem & Pharm Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.

SYN-Tech Chem & Pharm Co Ltd - Total Liabilities Trend (2015–2025)

This chart illustrates how SYN-Tech Chem & Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SYN-Tech Chem & Pharm Co Ltd asset portfolio.

SYN-Tech Chem & Pharm Co Ltd Competitors by Total Liabilities

The table below lists competitors of SYN-Tech Chem & Pharm Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Cellectis
PA:ALCLS
France €229.03 Million
Ryvu Therapeutics SA
WAR:RVU
Poland zł159.63 Million
Deleum Bhd
KLSE:5132
Malaysia RM279.88 Million
SinoMedia Holding Limited
F:SJY
Germany €107.21 Million
Social Commerce Partners Corporation Class A Ordinary Shares
NASDAQ:SCPQ
USA $3.63 Million
LI Ming Development Construction Co Ltd
TWO:6212
Taiwan NT$7.36 Billion
Fabryki Mebli Forte S.A.
WAR:FTE
Poland zł495.26 Million
New Asia Construction & Development Corp
TW:2516
Taiwan NT$5.00 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down SYN-Tech Chem & Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SYN-Tech Chem & Pharm Co Ltd (1777) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.14 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.12 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SYN-Tech Chem & Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SYN-Tech Chem & Pharm Co Ltd (2015–2025)

The table below shows the annual total liabilities of SYN-Tech Chem & Pharm Co Ltd from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 NT$369.57 Million
≈ $11.64 Million
+26.72%
2024-12-31 NT$291.65 Million
≈ $9.19 Million
-50.02%
2023-12-31 NT$583.48 Million
≈ $18.38 Million
+0.58%
2022-12-31 NT$580.13 Million
≈ $18.28 Million
-36.37%
2021-12-31 NT$911.71 Million
≈ $28.72 Million
+68.38%
2020-12-31 NT$541.46 Million
≈ $17.06 Million
-22.75%
2019-12-31 NT$700.89 Million
≈ $22.08 Million
-3.44%
2018-12-31 NT$725.85 Million
≈ $22.87 Million
+29.70%
2017-12-31 NT$559.62 Million
≈ $17.63 Million
+115.30%
2016-12-31 NT$259.92 Million
≈ $8.19 Million
+1.88%
2015-12-31 NT$255.12 Million
≈ $8.04 Million
--

About SYN-Tech Chem & Pharm Co Ltd

TWO:1777 Taiwan Biotechnology
Market Cap
$103.82 Million
NT$3.30 Billion TWD
Market Cap Rank
#19158 Global
#1060 in Taiwan
Share Price
NT$73.90
Change (1 day)
+0.27%
52-Week Range
NT$70.30 - NT$78.80
All Time High
NT$108.00
About

SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relax… Read more